Vincristine sulfate

目录号:S1241 别名: Leurocristine

Vincristine sulfate Chemical Structure

Molecular Weight(MW): 923.04

Vincristine sulfate通过与微管蛋白结合而抑制微管聚合,IC50为32 μM。

规格 价格 库存 购买数量  
RMB 582.05 现货
RMB 2229.59 现货
RMB 7118.45 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck该产品发表文献15篇:

客户使用该产品的5个实验数据:

  • for HXO-RB44 cells, IC50 values for VCR were changed in the different SG600 treatment groups. The results are representative of three independent  experiments and of f our replicates in each experiment.

    Int J Mol Sci 2012 13, 10736-10749 . Vincristine sulfate purchased from Selleck.

  • Plk inhibitor cooperates with chemotherapeutic agents. Conditional patched mutant tumor cells were treated with increasing concentrations of the chemotherapeutic agents vincristine alone or in combination with 10 nMol/L BI-2536. Cells were cultured for 48 hours, pulsed with 3H-Td, and harvested for analysis of 3H-Td incorporation at 66 hours.

    Cancer Research, 2013, 73(20): 6310-22 . Vincristine sulfate purchased from Selleck.

  • Determination of mutation frequencies in cells treated with chemotherapy drugs following caspase inhibition. TK6 cells were incubated with no inhibitor or 10 μM QVD then treated with the following drug doses: 300 ng/ml TRAIL, 0.7 μM cisplatin, 0.5 μM temozolomide, 3 nM doxorubicin, 0.5 nM SN38 or 0.07 nM vincristine. (a) Caspase activity was assessed by luminescent detection of Caspase-3/-7 Glo reagent after 5 h. After 24- h treatment, (b) clonogenicity assays were performed to determine the proportion of cells maintaining clonogenic competency after treatment, whereas (c) surviving cells were grown in 6TG to select for the emergence of any HPRT mutants. (d) Clonogenicity and (e) HPRT mutation assays were repeated in CASP3/7 DKO lines in the same manner. Error bars represent mean±S.E.M. from at least three independent experiments. Two-sided T-tests were used to calculate P-values.

    Cell Death & Disease, 2017, doi:10.1038/cddis.2017.454. Vincristine sulfate purchased from Selleck.

  • Discrimination of micronuclei induced by EMS and VCR in V79-hCYP2E1-hSULT1A1 cells as CENP-B negative or positive. The cells were treated with EMS (5 mM) or VCR (5 nM) for 6 h, followed by a recovery period of 18 h. They were stained for CENP-B (green) and β-tubulin (red) by the immunofluorescence assays, as described in Section 2.5. DNA was stained with DAPI (blue). The vertical and horizontal arrows indicate CENP-B-negative and CENP-B-positive micronuclei, respectively.

    Chemosphere, 2018, 210:467-475. Vincristine sulfate purchased from Selleck.

  • c Quantification of surviving colony numbers from clonogenic assays of D283 Med cells exposed to 10, 20, or 40 μM lomustine with or without 10 nM E2 (n = 6 for each group). d Quantification of colony number from clonogenic assays of D283 Med cells exposed to 5, 10, or 20 nM vincristine with or without 10 nM E2 (n = 8 for each group). All results are expressed as mean ± SEM. Significant differences from the control group were determined by two-way ANOVA followed by Holm-Sidak’s post-test analysis and is indicated above the error bars; * p ≤ .05

    BMC Pharmacol Toxicol, 2017, 18(1):63. Vincristine sulfate purchased from Selleck.

产品安全说明书

Microtubule Associated抑制剂选择性比较

生物活性

产品描述 Vincristine sulfate通过与微管蛋白结合而抑制微管聚合,IC50为32 μM。
靶点
Microtubules [1]
(Cell-free assay)
32 μM
体外研究

Vincristine抑制微管蛋白二聚体聚合亚单位,抑制它们的聚合作用,Ki为85 nM。[1]在低浓度时,Vincristine抑制纺锤体,使染色体分离失败,进而导致中期停滞,并抑制有丝分裂。在较高浓度时,Vincristine可能干扰且诱导全部微管解聚。[2] Vincristine 诱导肿瘤细胞凋亡,且抑制SH-SY5Y细胞增殖,IC50为0.1 µM。Vincristine诱导有丝分裂停滞,促进caspase-3和-9及cyclin B的表达,但降低cyclin D的表达。[3] Vincristine通过干扰微管功能而诱导神经毒性形成,这会导致轴突运输堵塞,从而导致轴突变性。[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HepG2.2.15 NVfHUnMzS2WubDDWbYFjcWyrdImgRZN{[Xl? NGLURnMxNTBwNTFOwG0> NVvUN|ZsOjRiaB?= MVvk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? NFnvTnAzPTZ4M{e2PS=>
HepG2-HBV1.1 NG\wTFBCeG:ydH;zbZMhSXO|YYm= M3LDUVAuOC53IN88US=> M1vPWFI1KGh? NYXzcoRRcW6mdXPld{BieG:ydH;zbZMh\G:|ZTDk[ZBmdmSnboTsfS=> NGqy[IkzPTZ4M{e2PS=>
HepG2.2.15 NVL2VGtiTnWwY4Tpc44hSXO|YYm= NHSyW5IxNjFizszN MWGyOEBp M4PtR5Bzd22xdHXzJIhmeGG2aYTpd{BDKH[rcoXzJJBzd3SnaX6g[ZhxemW|c3nvci=> NXzhb41WOjV4NkO3Olk>
HepG2-HBV1.1 NGTvRVFHfW6ldHnvckBCe3OjeR?= MlrqNE4yKM7:TR?= NH3lTHczPCCq NUDpNJg4eHKxbX;0[ZMhcGWyYYTpeIl{KEJidnnyeZMheHKxdHXpckBmgHC{ZYPzbY9v NYHsRopYOjV4NkO3Olk>
HepG2-HBV1.1 MkHpSpVv[3Srb36gRZN{[Xl? M4LVPFAvOSEQvF2= Mk\VOFghcA>? NG\BZ2hxem:vb4Tld{Bk\WyuIHX4Z5JmfGmxbjDv[kBp\XCjdHn0bZMhSiC4aYL1d{BvfWOuZX;jZZB{cWS|IHnud5Rm[WRib3[gbIVx[XSrdHnzJGIhfmm{dYOgSIFv\SCyYYL0bYNt\XN? MX[yOVY3Ozd4OR?=
HepG2-HBV1.1 M2DaZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\mUJlTOC5zIN88US=> NXfkZnB4OS13IHS= MUjpcohq[mm2czD0bIUheHKxbHnm[ZJifGmxbjD0bY1mKGSncHXu[IVvfGy7 NILMN28zPTZ4M{e2PS=>
HepG2-HBV1.1 M{\QUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXu3N4NvOC5zIN88US=> M3:0e|EuPSCm M3;Ge4lvcGmkaYTzJJRp\SCycn;sbYZmemG2aX;uJJRqdWViZHXw[Y5l\W62bIm= Mn[2NlU3PjN5Nkm=
HepG2-HBV1.1 M1TyWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHYNE4yKM7:TR?= NFXZblcyOi15MjDo MXLpcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2IHH0JHMueGijc3W= MUWyOVY3Ozd4OR?=
HepG2-HBV1.1 NF\TdoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnz5NE4yKM7:TR?= Mlz4NVIuPzJiaB?= NIr1WpVqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0JIF1KFNvcHjhd4U> MmiyNlU3PjN5Nkm=
Raji MknSSpVv[3Srb36gRZN{[Xl? NUTlZVV{OC53wrFOwG0> Mo\lO|IhcA>? MoP2ZYJwdGm|aHXzJIF2fG:yaHHnfeKh MXSyOVQ1PjN5Nx?=
SK-MEL-28  MnHrSpVv[3Srb36gRZN{[Xl? Ml\qN|Ahdk1? MU[2JIg> MXTpcoR2[2W|IFey5qCUVSClZXzsMYN6[2ynIHHydoV{fA>? MWeyOVMyOzBzMB?=
H157 MmrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1X0d2lEPTB;MT6wN{DDuSByLkC0JI1qfTKP NYf2d|FDOjV{NUe5NVE>
Jurkat NWnOblVwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XJfVEuOyCwTR?= MoLROFjDqGh? NXy3RoRTTE2VTx?= MnTC[IVkemWjc3XzJJZq[WKuZTDj[YxtKG63bXLldpMh\G:|ZTDk[ZBmdmSnboTsfS=> MlvSNlUyPTZzNE[=
CEM NF;4ZYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjpboQyNTNibl2= NYG2W3BsPDkEoHi= M{HEPWROW09? NULkO41J\GWlcnXhd4V{KH[rYXLs[UBk\WyuIH71cYJmenNiZH;z[UBl\XCnbnTlcpRtgQ>? NVrlcWI2OjVzNU[xOFY>
P12 NGjPdY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV6zbVRHOS1|IH7N NXzaUYJCPDkEoHi= NIWxT3pFVVOR NHTUUlhl\WO{ZXHz[ZMhfmmjYnzlJINmdGxiboXtZoVzeyCmb4PlJIRmeGWwZHXueIx6 Mn;ENlUyPTZzNE[=
KB MnWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\STWM2OD1yLkCwOFkhyrFiMD6wNFAyKM7:TR?= M3HLeVI2ODV6NUK2
KBv200 (ABCB1) NVi2UpcyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\BTWM2OD1yLkO0OlIhyrFiMD6wNFY3KM7:TR?= Mnu2NlUxPTh3Mk[=
SUDHL6  MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXZWZpzOeLCid88US=> MYC0PE84OiCq MmjkbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHlic3nncolncWOjboTsfS=> MVeyOFk3OTZyNB?=
SUDHL6  MojKSpVv[3Srb36gRZN{[Xl? NHfPUmYy6oDLzszN NIr4Z2g4OiCq M{DPXYlv\HWlZYOgd4lodmmoaXPhcpQh[XCxcITveIlkKG2xcoDoc4xw\3liY3jhcodmeyClb4Ty[ZN1\WRid3n0bEBDS0xzMVGgd4lTVkF? M1zLclI1QTZzNkC0
HCT-116 NUDFfXIyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo[xS2k2OD13IH7N NVTxPG9pOjR7Mke4OVc>
SKNBe2C Ml7VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzIfZptUUN3ME2zNk45yrF2LkCgcm0> MWWyOFkzOTl{MB?=
IGNR91 NFf0V3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jKfmlEPTB;MkSuN:KyOS55IH7N Ml21NlQ6OjF7MkC=
SKNAS Mk[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPKTWM2OD1zLkZCtVAvOiCwTR?= Mn\CNlQ6OjF7MkC=
LAN1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fZPWlEPTB;Mj6zxtExNjJibl2= MVyyOFkzOTl{MB?=
SHSY5Y NWLaSHlZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRThwMtMxNE43KG6P MnPiNlQ6OjF7MkC=
A549-WT NU\zRVV[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTXZVVEUUN3ME2xPU41OzdiwsGgNE42QTRiIH7N MYWyOFg2QDh{Nx?=
A549-R NYHododrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTLO2pKSzVyPUGyMlE4QCEEsTCwMlM{OyBibl2= M1vKOFI1QDV6OEK3
MCF-7-WT MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDXTWM2OD1zNz63OVIhyrFiMD6yNVghKG6P MXWyOFg2QDh{Nx?=
MCF-7-R NYrLNotST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7sTWM2OD13LkWzPUDDuSByLkG0OEAhdk1? MYCyOFg2QDh{Nx?=
A549-R MkSwR5l1d3SxeHnjbZR6KEG|c3H5 MYTJR|UxRTF{LkG3PEDDuSByLkOzN{BvVQ>? M2fqelI1QDV6OEK3
MCF-7-R M{\x[mN6fG:2b4jpZ4l1gSCDc4PhfS=> NIfzWoRKSzVyPUWuOVM6KMLzIECuNVQ1KG6P Mn;TNlQ5PTh6Mke=
SW620 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXBTWM2OD15LkiwJOKyKDBwMEigcm0> MmHlNlQ4OjZ5M{m=
SW620/AD300 M3HqbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvrUFFKSzVyPUmwPU43OCEEsTC4MlkyKG6P NIXFS3czPDd{NkezPS=>
HEK293/pcDNA3.1 M{D0NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2e1V2lEPTB;MT60OUDDuSByLkKwJI5O NHzPRY8zPDd{NkezPS=>
HEK293/ABCC1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGCz[|JKSzVyPUG5MlI6KMLzIEKuNFghdk1? Mn7NNlQ4OjZ5M{m=
TCC MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXiyOEBp MYPJR|UxRTdyIH7N MVmyOFcyPjl2NB?=
TCC NH7vfIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjkOFghcA>? NUjBOG13UUN3ME21NEBvVQ>? MmjWNlQ4OTZ7NES=
HepG2/ADM MkDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTJwN{i2N:KyOC5{M{exJO69VQ>? NIjLOGUzPDdyNEW1Oi=>
HepG2 MlXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFj2NGpKSzVyPUCuNFEyPcLzMD6wNFE4KM7:TR?= NGj2dHIzPDdyNEW1Oi=>
MCF-7/ADR MmLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo[zTWM2OD12LkS4NlbDuTBwMkC3NEDPxE1? MYOyOFcxPDV3Nh?=
MCF-7 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFyzfmlKSzVyPUCuNFE2QcLzMD6wNFYzKM7:TR?= M170[VI1PzB2NUW2
A-172  MnHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfLVWF1OC5zwrFOwG0> MVyyOE84OiCq Ml7UbY5pcWKrdIOgZ4VtdCCpcn;3eIghfGmvZTDk[ZBmdmSnboTsfS=> NGW1dowzPDV|MEKzOS=>
U-251MG MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGWzW3QxNjIEoN88US=> MXmyOE84OiCq NHv0OmNqdmirYnn0d{Bk\WyuIHfyc5d1cCC2aX3lJIRmeGWwZHXueIx6 MnvrNlQ2OzB{M{W=
DLD-1 M2HRPWZ2dmO2aX;uJGF{e2G7 NVu2T2NSOTByIH7N NXzl[XE1PDhiaB?= M1fMTJBzd22xdHXzJHJWVlh|IHTlcYV1cHmuYYTpc47DqA>? NY\VZ3JkOjR2MEO0OVM>
CCD18Co NGHC[YdHfW6ldHnvckBCe3OjeR?= NWDG[3B5OTByIH7N MnK5OFghcA>? MUDwdo9ud3SnczDSWW5ZOyCmZX3leIh6dGG2aX;uxsA> NGjrfYMzPDRyM{S1Ny=>
DLD-1 M2W0ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGP5[GsxNTFyMECgcm0> NYS3RXZDPDhiaB?= NWH4bWR{cW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? NHzmRlEzPDRyM{S1Ny=>
CCD18Co NWnJOFhQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPySWExNTFyMECgcm0> MlHnOFghcA>? NUPqXoZGcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? NGqydZQzPDRyM{S1Ny=>
HepG2 NFOxbnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3P2RVI1KGh? MU\JR|UxRTV{LkZihKnPxE1? NILBWJAzPDN2MU[4PC=>
HEK293/pcDNA3.1 M3\tNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\qRmlEPTB;MD6wNFTDuTBwMECwN{DPxE1? MV:yOFI5PDd6Mx?=
HEK293/MRP1 MnXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\j[GNJUUN3ME2wMlA2PcLzMD6wNVIxKM7:TR?= MnvFNlQzQDR5OEO=
Ramos M2TzcGFxd3C2b4Ppd{BCe3OjeR?= MmfCNwKBkc7:TR?= MWK0PEBp MVnpcoR2[2W|IEO0MlYmyrFzLkmyKUBieG:ydH;zbZM> NVvOb2g3OjR{NU[0PVE>
NCI-H1299/pcDNA3 Mlu5R4VtdCCYaXHibYxqfHliQYPzZZk> M{jGd|AuOjBibl2= NEDwOXk6PiCq NITycWFqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 MlXYNlQyPzdyMUK=
H1299/ICAM-3 MoLSR4VtdCCYaXHibYxqfHliQYPzZZk> MojHNE0zOCCwTR?= MYK5OkBp NYPQRVlEcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= Mk[5NlQyPzdyMUK=
NCI-H1299/pcDNA3 NHzP[FVHfW6ldHnvckBCe3OjeR?= MVyxM|UwOTBxMkFCpI5O M4Lzc|k3KGh? NXLj[4FYcW6mdXPld{BkdGWjdnHn[UBw\iClYYPwZZNmey1|LDC4MEA6NCCjbnSgVGFTWA>? MXuyOFE4PzBzMh?=
H1299/ICAM-3 MkHDSpVv[3Srb36gRZN{[Xl? NGKwR3cyNzVxMUCvNlDDqG6P M1jQelk3KGh? MlrqbY5lfWOnczDjcIVifmGpZTDv[kBk[XOyYYPld{0{NCB6LDC5MEBidmRiUFHSVC=> MYWyOFE4PzBzMh?=
W1 Ml[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jITWlEPTB;MD6wNFMzKM7:TR?= NYr6NYVLOjRzNECxO|Y>
W1VR M3\GOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLWTWM2OD1yLkC1OkDPxE1? MVGyOFE1ODF5Nh?=
K562 NH\FOlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;IPWlEPTB;MD6wN|IhyrFiMD6wNFEhKM7:TR?= M1e1fFI1OTN3OUO3
K562/ADR Mmi1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIn1PVBKSzVyPUOuNlYyKMLzIECuOFEzKM7:TR?= NGTDbHUzPDF|NUmzOy=>
K562 NF\2U5NCeG:ydH;zbZMhSXO|YYm= MWiwMlMh|ryP MXGyOEBp NXfGfopkcW6mdXPld{BieG:ydH;zbZMhe2mpbnnmbYNidnSueR?= MmDSNlQyOzV7M{e=
K562/ADR Mnf5RZBweHSxc3nzJGF{e2G7 NI\HTFU{KM7:TR?= MVeyOEBp NWLZd2c2cW6mdXPld{BieG:ydH;zbZM> NYfrbJFLOjRzM{W5N|c>
A549 M4PpeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTBwMUCgxtEhOC5yMzFOwG0> M3rMdlI{QTdzMEe1
K562 MnXRR4VtdCCYaXHibYxqfHliQYPzZZk> M{fVdVMvPzYkgKO2NOKhdk1? MVG3NuKhcMLi MkHBbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? MXuyN|g4PzJ{Mx?=
lucena M{W3OWNmdGxiVnnhZoltcXS7IFHzd4F6 MXSzMlc26oDVNkFCpI5O MXO3NuKhcMLi NFrY[pNvdyCnZn\lZ5Q> M{nOWFI{QDd5MkKz
FEPS M{TvVmNmdGxiVnnhZoltcXS7IFHzd4F6 NVnDeXd6Oy55NfMAl|YxyqCwTR?= MkP6O|LDqGkEoB?= MYjuc{Bm\m[nY4S= NIHGTGszOzh5N{KyNy=>
A2780 NEfPfIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofxTWM2OD1|LkWgcW0> NFnmcmQzOzh{OUKwNy=>
ACHN Mnf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXwTWM2ODxyLkGgcW0> NHTFdVMzOzh{OUKwNy=>
U-937 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRDN2IH7N MnPxNlM5Ojl{MEO=
Jurkat M3LaU2Fxd3C2b4Ppd{BCe3OjeR?= NYXWOlFsPcLizsznM41tyqB? MmjiNlQhcA>? MXPpcoR2[2W|IHHwc5B1d3OrczDzbYdvcW[rY3HueIx6 NEnFPHkzOzhzMESwPS=>
Jurkat NIPRNmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjNUVU2yqEQvHevcYzDqA>? M1zWSFI1KGh? M2jPcIFzemW|dDDKeZJs[XRiY3XscJMhcW5iR{KvUUBxcGG|ZR?= M1TwV|I{QDFyNEC5
Hep-2 NI\tcZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTTTWM2OD1yLkC0xtExNjBzIN88US=> M3;PTVI{PzhyNEK0
Hep-2/v MoX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPETWM2OD1zLklCtVAvOjBizszN NEPNO|gzOzd6MESyOC=>
SGC-7901 NVvCPGhQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVKwMVExKM7:Zz;tcC=> M2jMWlI1NzR6L{eyJIg> MYDpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK= MnvtNlM4PDN3N{K=
SGC-7901/VCR NFXVTFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXKzZ2Q1OC1zMDFOwIcwdWx? MkG0NlQwPDhxN{KgbC=> MknqbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy MoTsNlM4PDN3N{K=
SGC-7901 NVfwclY6SXCxcITvd4l{KEG|c3H5 Mo\rbY5lfWOnczDhdI9xfG:|aYOgd4lodmmoaXPhcpRtgQ>? MkS2NlM4PDN3N{K=
SGC-7901/VCR M{jNN2Fxd3C2b4Ppd{BCe3OjeR?= NEDaU|FqdmS3Y3XzJIFxd3C2b4Ppd{B{cWewaX\pZ4FvfGy7 NWjVdYJuOjN5NEO1O|I>
KB-3-1 NWf4doMxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\jd2lEPTB;MT62OkDDuSByLkG2NkDPxE1? NE\TWHMzOzZ5M{S0OS=>
KB-C2 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTJyMj61OkDDuSB2Mj60PFEh|ryP NFG0SY8zOzZ5M{S0OS=>
KB-3-1 M3\PT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnkTWM2OD1zLkK2JOKyKDBwMEK3JO69VQ>? NUDtSlBTOjN4N{O0OFU>
KB-V1 M1Lyb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXGTWM2OD1{MEiuPFUhyrFiMkCuOEDPxE1? Mm\aNlM3PzN2NEW=
HEK293/pcDNA3.1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTJ2LkGgxtEhOC5{MESg{txO MVWyN|Y4OzR2NR?=
HEK293/ABCB1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTN3MUKuPEDDuSB|N{iuN|kyKM7:TR?= MYmyN|Y4OzR2NR?=
A549/EGFP  MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrGWFcxNjBzLUGwNFAh|ryP NEfTVY5KSzVyPUi2MlchyrFiMkmuNUDPxE1? NIOzTHYzOzZ|NEK4Ni=>
A549/Slug NVPoeXdFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH6wfY0xNjBzLUGwNFAh|ryP NFPvRYtKSzVyPUmuO{DDuSB|LkGg{txO MlHKNlM3OzR{OEK=
JFCR39  NFLMcohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHNVGtOOSEEtV2= NInBdXYzPCCq MVfEUXNQ MYPtZZJs\WSueTDpcoNz\WG|ZYOgeIhmKG63bXLldkBw\iCJMj;NJJBp[XOnIHPlcIx{ NFLGfpIzOzV7OEK3Oi=>
A549 M1jFPWZ2dmO2aX;uJGF{e2G7 MofFNVAxKG6P NXHrT2tGOTZiaB?= M{fjUWROW09? NE\McWtt\WGmczD0c{BiKGyxc4Ogc4YhdWmlcn;0eYJ2dGW| MkWxNlM2QTh{N{[=
SGC7901 MnzOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljGTWM2OD1zLkK25qCKyrIkgJmwMlEyKM7:Zz;tcC=> MWiyN|U3PDR6Mh?=
SGC7901/LV-NC NESzdZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX60eVhlUUN3ME2xMlc46oDLwsJihKkxNjF4IN88[{9udA>? NEPWVYUzOzV4NES4Ni=>
SGC7901/LV-SGO1 M3[2Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTRwM{dihKnDueLCiUCuN|ch|rypL33s MUGyN|U3PDR6Mh?=
SGC7901/VCR NHTlN5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLue|ZiUUN3M{2yNE42O+LCidMx5qCKOS57NjFOwIcwdWx? NY\GdFJ6OjN3NkS0PFI>
SGC7901/VCR-NC M17jVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLSTWM2OD1zOT64OwKBkcLz4pEJNk4xOSEQvHevcYw> MYOyN|U3PDR6Mh?=
SGC7901/VCR-si-SGO1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvvV4VKSzVyPU[uNVjjiIoEsfMAjVEvODNizsznM41t M1focVI{PTZ2NEiy
SGC7901/ADR MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTdwOEZihKnDueLCiUCuOlQh|rypL33s MmPlNlM2PjR2OEK=
SGC7901/ADR-NC NIDSRZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRThwOURihKnDueLCiUCuOlgh|rypL33s NEPiZWszOzV4NES4Ni=>
SGC7901/ADR-si-SGO1 NVjnemJDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XIW2lEPTB;Mz60OwKBkcLz4pEJNE4zQSEQvHevcYw> MmTyNlM2PjR2OEK=
SH-SY5Y  MlTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFH0PYsxNjByMT2xNEDPxE1? MoDBNlQhcA>? NH\NSXNKSzVyPUCuNVE{yrFyLkCxNkDPxE1? Mo[4NlMyOjlyNkW=
SH-SY5Y  NGDRc3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvi[VFkOC5yMEGtNVAh|ryP MVm0PEBp MmPJTWM2OD1yLkC3POKyOC5yMEmg{txO MlW0NlMyOjlyNkW=
SH-SY5Y  M4CzeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWm5ZmZDOC5yMEGtNVAh|ryP MnHjO|IhcA>? NHuwbnBKSzVyPUCuNFUyyrFyLkCwPEDPxE1? M2rZUFI{OTJ7ME[1
SH-SY5Y NFnEeFVCeG:ydH;zbZMhSXO|YYm= MXmwMlEh|ryP M1W1NFAuOjRiaB?= MnvHbY5lfWOnczDhdI9xfG:|aYOgc4YhW0hvU2m1XUBk\WyuczDmc4xtd3erbnegZ4VtdCCleXPs[UBienKnc4SgZZQhfGinIFeyM20heGijc3W= MoDENlMyOjlyNkW=
SH-SY5Y M3[xcGFxd3C2b4Ppd{BCe3OjeR?= MUCwMlEh|ryP NEfpVVgxNTJ2IHi= NH21XY1qdmS3Y3XzJI1qfG:2aXOgZZJz\XO2wrC= NV\EcVVqOjNzMkmwOlU>

... Click to View More Cell Line Experimental Data

体内研究 Vincristine 按3 mg/kg剂量单独腹腔注射给药携带双侧皮下移植瘤RH12或RH18的小鼠,平均生长延迟120天和52天以上,且再植指数分别为0.06%和5%。[5] Vincristine 处理小鼠,通过宿主细胞介导的血管效应及直接的微管蛋白介导的的细胞毒性作用而对皮下结肠38肿瘤起作用。Vincristine (5 mg/kg) 降低肿瘤血流量,降低近75%。[6]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

细胞实验:[1]
+ 展开
  • Cell lines: B16 黑色素瘤细胞
  • Concentrations: 10 nM
  • Incubation Time: 3 天
  • Method: 细胞按5 × 104 cells/mL的浓度接种在含2 mL培养基的35-mm 实验板上,在37°C下 含5% CO2 和95% 空气 的环境下生长24小时。然后使用有或无10 nM药物的新鲜培养基更换原来的培养基,继续增殖3天。使用胰蛋白酶和EDTA将细胞分离后,每天使用库氏计数器完成细胞计数
    (Only for Reference)
动物实验:[5]
+ 展开
  • Animal Models: 携带人类横纹肌肉瘤移植瘤Rh12的鼠
  • Formulation: 水溶液
  • Dosages: 3 mg/kg
  • Administration: 腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 100 mg/mL (108.33 mM)
Water 60 mg/mL (65.0 mM)
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
Saline
30 mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 923.04
化学式

C46H58N4O14S

CAS号 2068-78-2
稳定性 powder
in solvent
别名 Leurocristine

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03571321 Not yet recruiting Acute Lymphoblastic Leukemia|ALL Childhood|ALL University of Chicago|Incyte Corporation September 5 2019 Phase 1
NCT03571321 Not yet recruiting Acute Lymphoblastic Leukemia|ALL Childhood|ALL University of Chicago|Incyte Corporation September 5 2019 Phase 1
NCT03349281 Recruiting Refractory Acute Lymphoblastic Leukemia|Relapsed Acute Lymphoblastic Leukemia Julio Barredo|Takeda|University of Miami June 2019 Phase 1
NCT03349281 Recruiting Refractory Acute Lymphoblastic Leukemia|Relapsed Acute Lymphoblastic Leukemia Julio Barredo|Takeda|University of Miami June 2019 Phase 1
NCT03871257 Not yet recruiting Low Grade Glioma|Neurofibromatosis Type 1|Visual Pathway Glioma National Cancer Institute (NCI) May 3 2019 Phase 3
NCT03864419 Not yet recruiting Burkitt Lymphoma|KSHV-associated Multicentric Castleman Disease|Diffuse Large B-Cell Lymphoma Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI) May 4 2019 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    I want to use the product #S1421 for mouse in vivo, could you please give us your advice about administration method?

  • 回答:

    According to the reference cited on our website, we test the solubility of S1421 Staurosporine in 4% DMSO/saline, and it is a suspension at 5 mg/mL. The compound can also be dissolved in the vehicle 4% DMSO/30% PEG 300/10% Tween 80/saline at 5 mg/ml as a clear solution for injection.

Microtubule Associated Signaling Pathway Map

相关Microtubule Associated产品

Tags: 购买Vincristine sulfate | Vincristine sulfate供应商 | 采购Vincristine sulfate | Vincristine sulfate价格 | Vincristine sulfate生产 | 订购Vincristine sulfate | Vincristine sulfate代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID